Research programme: cancer therapies - KeryxAlternative Names: KRX 0404
Latest Information Update: 26 May 2010
At a glance
- Originator Keryx Biopharmaceuticals
- Mechanism of Action Apoptosis stimulants; Signal transduction pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Jul 2009 No development reported - Preclinical for Cancer in USA (IV)
- 01 May 2007 Preclinical trials in Cancer in USA (IV)